B. Riley lifts Eton Pharmaceuticals price target to $81
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
B. Riley Financial raised its price target on Eton Pharmaceuticals (NASDAQ:ETON) to $81 from $70 while keeping a "buy" rating, implying upside of more than 20%. The move follows quarterly results in which the specialty pharmaceutical company beat analyst expectations with EPS of $0.50 and revenue of $57.93 million.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.